What is TECLens?
TECLens is a clinical-stage medical device company headquartered in Stamford, CT. The company is focused on developing a proprietary, non-invasive cornea cross-linking procedure, CXLens®, designed to treat conditions such as keratoconus, low-order myopia, and presbyopia. Their technology utilizes a single-use disposable contact lens and a control system capable of treating both eyes simultaneously for keratoconus, while also offering integrated real-time ultrasound feedback and patterned ultraviolet light delivery for refractive indications. TECLens aims to provide a safe, simple, and permanent alternative to existing vision correction methods like LASIK, contact lenses, and eyeglasses.
How much funding has TECLens raised?
TECLens has raised a total of $10.5M across 2 funding rounds:
Private Equity
$1.2M
Series A
$9.3M
Private Equity (2017): $1.2M, investors not publicly disclosed
Series A (2025): $9.3M led by Rimonci Capital, Sunmed Capital, Johnson & Johnson Innovation, and Yonjin Venture
Key Investors in TECLens
Rimonci Capital
Rimonci Capital is a firm specializing in China-Israel cross-border investments, focusing on medical devices and cybersecurity, aiming to create value through intensive business development and strategic M&A opportunities.
Sunmed Capital
Sunmed Capital operates within the Venture Capital & Private Equity sector, indicating a strategic interest in funding companies with high growth potential in the medical technology space.
Johnson & Johnson Innovation
Johnson & Johnson Innovation is a global entity dedicated to advancing human health through strategic partnerships, focusing on developing transformative healthcare solutions across consumer products, medical devices, and pharmaceuticals.
What's next for TECLens?
With the recent infusion of major strategic capital, TECLens is poised to accelerate its development and commercialization efforts. The substantial enterprise-level funding suggests a focus on scaling operations, advancing clinical trials, and potentially expanding its market reach. This strategic investment will likely enable TECLens to further refine its CXLens® technology and pursue regulatory approvals, positioning the company for significant growth in the ophthalmic device market.
See full TECLens company page
